Mitchel Sayare replaces John Pappajohn as PharmAthene's chairman
This article was originally published in Scrip
Executive Summary
PharmAthene, a biodefence company developing medical countermeasures against biological and chemical threats, has elected Dr Mitchel Sayare chairman of the board, succeeding John Pappajohn who has stepped down from the board. Dr Sayare has been a PharmAthene board member since April 2010, and previously served from 1985 to 2010 as chairman and CEO of ImmunoGen.